For older patients with cancer and T2D, GLP-1 RA use is associated with lower all-cause mortality than DPP4i use.

For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is ...

Precision cancer treatment on a larger scale is moving closer after researchers have developed an AI platform that can tailor protein components and arm the patient's immune cells to fight cancer.